📊 OBIO Key Takeaways
Is Orchestra BioMed Holdings, Inc. (OBIO) a Good Investment?
Orchestra BioMed demonstrates exceptional 1169% revenue growth and maintains a solid balance sheet with low leverage, but faces critical fundamental challenges with a $49M annual operating cash burn against $33.5M revenue, yielding approximately 8-9 months of cash runway at current rates. The company must achieve significant operating leverage and path to profitability within months or face capital raise dilution.
Why Buy Orchestra BioMed Holdings, Inc. Stock? OBIO Key Strengths
- Exceptional revenue growth of 1169% YoY indicating strong market demand and product adoption
- Healthy balance sheet with low debt-to-equity ratio (0.28x) and positive stockholders' equity of $53.6M
- Strong liquidity position with 6.45x current ratio and $34.7M in cash reserves
OBIO Stock Risks: Orchestra BioMed Holdings, Inc. Investment Risks
- Unsustainable operating cash burn of $49M annually against $33.5M revenue creates severe negative unit economics
- Severe and widening operating losses (-$51.8M) with net margin of -157.4% demonstrates inability to convert revenue to profit
- Operating expenses exceed revenue by 155%, leaving minimal cash runway before additional capital raise required
Key Metrics to Watch
- Operating cash flow - must trend toward positive or company faces existential runway risk
- Gross margin and operating expense ratio - critical to demonstrate operating leverage as revenue scales
- Quarters until capital raise - timeline for next funding event and potential shareholder dilution
Orchestra BioMed Holdings, Inc. (OBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.45x current ratio provides a solid financial cushion.
OBIO Profit Margin, ROE & Profitability Analysis
OBIO vs Healthcare Sector: How Orchestra BioMed Holdings, Inc. Compares
How Orchestra BioMed Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Orchestra BioMed Holdings, Inc. Stock Overvalued? OBIO Valuation Analysis 2026
Based on fundamental analysis, Orchestra BioMed Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Orchestra BioMed Holdings, Inc. Balance Sheet: OBIO Debt, Cash & Liquidity
OBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Orchestra BioMed Holdings, Inc.'s revenue has grown significantly by 848% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.66 indicates the company is currently unprofitable.
OBIO Revenue Growth, EPS Growth & YoY Performance
OBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $861.0K | -$13.5M | $-0.40 |
| Q2 2025 | $778.0K | -$13.5M | $-0.45 |
| Q1 2025 | $620.0K | -$13.5M | $-0.38 |
| Q3 2024 | $419.0K | -$10.9M | $-0.38 |
| Q2 2024 | $778.0K | -$10.9M | $-0.35 |
| Q1 2024 | $620.0K | -$10.9M | $-0.38 |
| Q3 2023 | $419.0K | -$5.7M | $-0.38 |
| Q2 2023 | $401.0K | -$5.7M | $-0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Orchestra BioMed Holdings, Inc. Dividends, Buybacks & Capital Allocation
OBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Orchestra BioMed Holdings, Inc. (CIK: 0001814114)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OBIO
What is the AI rating for OBIO?
Orchestra BioMed Holdings, Inc. (OBIO) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OBIO's key strengths?
Claude: Exceptional revenue growth of 1169% YoY indicating strong market demand and product adoption. Healthy balance sheet with low debt-to-equity ratio (0.28x) and positive stockholders' equity of $53.6M.
What are the risks of investing in OBIO?
Claude: Unsustainable operating cash burn of $49M annually against $33.5M revenue creates severe negative unit economics. Severe and widening operating losses (-$51.8M) with net margin of -157.4% demonstrates inability to convert revenue to profit.
What is OBIO's revenue and growth?
Orchestra BioMed Holdings, Inc. reported revenue of $33.5M.
Does OBIO pay dividends?
Orchestra BioMed Holdings, Inc. does not currently pay dividends.
Where can I find OBIO SEC filings?
Official SEC filings for Orchestra BioMed Holdings, Inc. (CIK: 0001814114) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OBIO's EPS?
Orchestra BioMed Holdings, Inc. has a diluted EPS of $-1.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Orchestra BioMed Holdings, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OBIO stock overvalued or undervalued?
Valuation metrics for OBIO: ROE of -98.4% (sector avg: 15%), net margin of -157.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OBIO stock in 2026?
Our dual AI analysis gives Orchestra BioMed Holdings, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OBIO's free cash flow?
Orchestra BioMed Holdings, Inc.'s operating cash flow is $-49.0M, with capital expenditures of $489.0K. FCF margin is -147.7%.
How does OBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -157.4% (avg: 12%), ROE -98.4% (avg: 15%), current ratio 6.45 (avg: 2).